Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 5 51-5, 2005, Pages

  Rasouli, Neda ^a,b   Raue, Ulrika ^a   Miles, Leslie M ^a   Lu, Tong ^a   Di Gregorio, Gina B ^a   Elbein, Steven C ^a   Kern, Philip A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Ectopic fat; Lipotoxicity; Metformin; Thiazolidinediones

Indexed keywords

INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECTOPIC TISSUE; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID OXIDATION; LIPID STORAGE; MALE; MUSCLE BIOPSY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS TISSUE; TISSUE DISTRIBUTION; WEIGHT GAIN;

ADIPOSE TISSUE; ADULT; AGED; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; METFORMIN; MIDDLE AGED; MUSCLES; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 17444420663     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00522.2004     Document Type: Article

References (31)

1. Bergman RN, Ider YZ, Bowden CR, and Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E667-E677, 1979.
2. Bergman RN, Prager R, Volund A, and Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790-800, 1987.
3. Billeter R, Weber H, Lutz H, Howald H, Eppenberger HM, and Jenny E. Myosin types in human skeletal muscle fibers. Histochemistry 65: 249-259, 1980.
4. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, and Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51: 2796-2803, 2002.
5. Burant CF, Sreenan S, Hirano K, Tai T-AC, Ohmiller J, Lukens J, Davidson NO, Ross S, and Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900-2908, 1997.
6. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, and Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106: 1221-1228, 2000.
7. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88: 787-835, ix, 2004.
8. Flegal KM, Carroll MD, Ogden CL, and Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727, 2002.
9. Friedman J. Fat in all the wrong places. Nature 415: 268-269, 2002.
10. Gray RE, Tanner CJ, Pories WJ, MacDonald KG, and Houmard JA. Effect of weight loss on muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab 284: E726-E732, 2003.
11. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19, 2003.
12. Kern PA, Simsolo RB, and Fournier M. Effect of weight loss on muscle fiber type, fiber size, capillarity, and succinate dehydrogenase activity in humans. J Clin Endocrinol Metab 84: 4185-4190, 1999.
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, and Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.
14. Li B, Nolte LA, Ju JS, Han DH, Coleman T, Holloszy JO, and Semenkovich CF. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6: 1115-1120, 2000.
15. Malenfant P, Joanisse DR, Theriault R, Goodpaster BH, Kelley DE, and Simoneau JA. Fat content in individual muscle fibers of lean and obese subjects. Int J Obes Relat Metab Disord 25: 1316-1321, 2001.
16. Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, and Henry RR. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metab Clin Exper 52: 540-546, 2003.
17. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, and Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797-802, 2002.
18. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, and Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343, 2002.
19. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
20. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, and Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346: 570-578, 2002.
21. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, and Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48: 1600-1606, 1999.
22. Petersen KF, Dufour S, Befroy D, Garcia R, and Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664-671, 2004.
23. Phillips DI, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, and Taylor R. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metab Clin Exper 45: 947-950, 1996.
24. Pulawa LK and Eckel RH. Overexpression of muscle lipoprotein lipase and insulin sensitivity. Curr Opin Clin Nutr Metab Care 5: 569-574, 2002.
25. The Diabetes Prevention Program. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 52: A58-A59, 2003.
26. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, and Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001.
27. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319-336, 2002.
28. Vidalpuig AJ, Considine RV, Jimenezlinan M, Werman A, Pories WJ, Caro JF, and Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues-effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422, 1997.
29. White LJ, Ferguson MA, McCoy SC, and Kim H. Intramyocellular lipid changes in men and women during aerobic exercise: a (1)H-magnetic resonance spectroscopy study. J Clin Endocrinol Metab 88: 5638-5643, 2003.
30. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Kara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.
31. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, and Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417, 2001.